Mouse models of Huntington's disease

Trends Pharmacol Sci. 2002 Jan;23(1):32-9. doi: 10.1016/s0165-6147(00)01884-8.

Abstract

Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder. In 1993 the mutation that causes HD was identified as an unstable expansion of CAG repeats in the IT15 gene. Since then one of the most important advances in HD research has been the generation of various mouse models that enable the exploration of early pathological, molecular and cellular abnormalities produced by the mutation. In addition, these models have made it possible to test different pharmacological approaches to delay the onset or slow the progression of HD. In this article, insights gained from mouse models towards the understanding of HD and the design of new therapeutic strategies are discussed.

Publication types

  • Review

MeSH terms

  • Animals
  • Creatine / therapeutic use
  • Dichloroacetic Acid / therapeutic use
  • Enzyme Inhibitors / therapeutic use
  • Humans
  • Huntingtin Protein
  • Huntington Disease / drug therapy
  • Huntington Disease / genetics*
  • Huntington Disease / pathology
  • Mice
  • Mice, Knockout
  • Mice, Transgenic
  • Minocycline / therapeutic use
  • Models, Animal*
  • Mutation
  • Nerve Tissue Proteins / genetics
  • Nuclear Proteins / genetics
  • Proteins / genetics
  • Trinucleotide Repeat Expansion

Substances

  • Enzyme Inhibitors
  • HTT protein, human
  • Htt protein, mouse
  • Huntingtin Protein
  • Nerve Tissue Proteins
  • Nuclear Proteins
  • Proteins
  • Dichloroacetic Acid
  • Minocycline
  • Creatine